Tamayo Louis Edward 4

4 · Lexeo Therapeutics, Inc. · Filed Feb 6, 2026

AI-generated summary of this filing

Updated Feb 6, 2026

Lexeo (LXEO) CFO Louis E. Tamayo Receives RSU Award

What Happened

Louis Edward Tamayo, Chief Financial Officer of Lexeo Therapeutics (LXEO), received equity awards on February 4, 2026 totaling 271,330 restricted stock units (RSUs): 44,665 RSUs (reported as acquisition) and 226,665 RSUs (reported as derivative acquisition). Each award is reported at $0.00 (these are compensation grants, not open-market purchases).

Key Details

Transaction date: February 4, 2026; Form 4 filed February 6, 2026.
Reported amounts/prices: 44,665 RSUs @ $0.00 and 226,665 RSUs (derivative) @ $0.00; total 271,330 RSUs.
Shares owned after transaction: not specified in the provided filing details.
Footnotes of note:
- F1/F2: These awards are RSUs. F1: 25% of the RSUs vest on February 15, 2027, then 1/16th vest on the issuer’s standard quarterly vesting dates thereafter, subject to continued service. F2 reiterates the securities are RSUs.
- F3: Separately describes an option vesting schedule (25% vest Feb 4, 2027, then 1/48th monthly thereafter); appears to apply to option-type awards and may reflect other equity arrangements.
Filing timeliness: Form filed two days after the grant date (Feb 6 filing for Feb 4 report); no late-filing flag noted in the provided data.

Context

RSUs are compensation awards that convert into shares only as they vest; they are not immediate cash purchases or open-market trades. These grants reflect executive compensation/retention mechanics rather than a direct bullish or bearish market signal.
For retail investors, vesting schedules determine when the CFO may acquire actual shares; any future sale would be reported separately.

Form 4

Period: 2026-02-04

Chief Financial Officer

Transactions

Award
Common Stock
[F1][F2]
2026-02-04+44,665→ 89,665 total
Award
Stock Option (right to buy)
[F3]
2026-02-04+226,665→ 226,665 total
Exercise: $7.27Exp: 2036-02-03→ Common Stock (226,665 underlying)

Footnotes (3)

[F1]The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
[F2]The reported securities are RSUs.
[F3]25% of the shares underlying the option vest and become exercisable on February 4, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

Signature

/s/ Youjin Choi, Attorney-in-Fact|2026-02-06

1 file